Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Varalakshmi Velagacherla"'
Publikováno v:
F1000Research, Vol 12 (2024)
Background Nintedanib (NTB) is a multiple tyrosine kinase inhibitor, been investigated for many disease conditions like idiopathic pulmonary fibrosis (IPF), systemic sclerosis interstitial lung disease (SSc-ILD) and non-small cell lung cancer (NSCLC)
Externí odkaz:
https://doaj.org/article/fc4f5787387f4d53ac24cbeaa94861db
Autor:
Shravya MACHERLA, Jothi VARGHESE, Usha Y NAYAK, Varalakshmi VELAGACHERLA, Richard LOBO, Viswanatha U, Vinayak KAMATH
Publikováno v:
Journal of Applied Oral Science, Vol 32 (2024)
Abstract The prevalence of gingivitis is substantial within the general population, necessitating rigorous oral hygiene maintenance. Objective This study assessed a Garcinia indica (GI) fruit extract-based mouthrinse, comparing it to a 0.1% turmeric
Externí odkaz:
https://doaj.org/article/6f74e138f5ac40daadbd809a6582e7eb
Publikováno v:
Viruses, Vol 15, Iss 1, p 213 (2023)
The coronavirus disease (COVID-19) is a pandemic that started in the City of Wuhan, Hubei Province, China, caused by the spread of coronavirus (SARS-CoV-2). Drug discovery teams around the globe are in a race to develop a medicine for its management.
Externí odkaz:
https://doaj.org/article/e274583649d1400a9698c7e7186e6878
Publikováno v:
Current Pharmaceutical Design. 29:1069-1091
Abstract: The expression “as sure as night follows a day” emulates those certain cycles in the environment that are always stable. Circadian rhythms are a group of processes that occur within the body in synchronisation with the external factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11acbf428f7e27af45dbfe187490a591
https://doi.org/10.2174/1381612829666230423144232
https://doi.org/10.2174/1381612829666230423144232
Autor:
Prateeksha Prakash Kamath, Rutu Rajeevan, Swastika Maity, Yogendra Nayak, Reema Narayan, Chetan Hasmukh Mehta, Varalakshmi Velagacherla, Anjaneyulu Konuri, Usha Yogendra Nayak
Publikováno v:
Journal of Applied Pharmaceutical Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ed6c07bd573240c3237ef3255e65a4d
https://doi.org/10.7324/japs.2023.130106-1
https://doi.org/10.7324/japs.2023.130106-1
Publikováno v:
Expert opinion on drug delivery. 18(11)
Nintedanib (N.T.B) is an orally administered tyrosine kinase inhibitor that has been approved recently by U.S.F.D.A for idiopathic pulmonary fibrosis (I.P.F) and systemic sclerosis-associated interstitial lung disease (S.Sc-I.L.D). N.T.B is also pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::388a29a6915b268efa8f08a65def3f68
https://pubmed.ncbi.nlm.nih.gov/34556001
https://pubmed.ncbi.nlm.nih.gov/34556001
Publikováno v:
Viruses; Volume 15; Issue 1; Pages: 213
Background: Coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is now a pandemic which began in Wuhan province of China. Drug discovery teams around the globe are in a race to develop a medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120b6be3e803424dd3315cb16a78a24b
https://doi.org/10.21203/rs.3.rs-101359/v1
https://doi.org/10.21203/rs.3.rs-101359/v1
Publikováno v:
Life Sciences. 291:120283
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with unknown etiological factors that can progress to other dangerous diseases like lung cancer. Environmental and genetic predisposition are the two major etiological or risk factors involv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67bd3e84690c4b5017535bae31fcbd54
https://doi.org/10.1016/j.lfs.2021.120283
https://doi.org/10.1016/j.lfs.2021.120283